Acquired Hemophilia A successfully treated with rituximab

Acquired Hemophilia A successfully treated with rituximab

Acquired hemophilia A (AHA) is a rare bleeding disorder due to the development of specific autoantibodies against factor VIII. The anti-CD20 monoclonal antibody Rituximab has been proven to be effective in  obtaining a long-term suppression of inhibitors of AHA,  besides other immunosuppressive stan...

Full description

Bibliographic Details
Main Authors: Giovanni D'Arena, Elvira Grandone, Matteo Nicola Dario Di Minno, Pellegrino Musto, Giovanni Di Minno
Format: Article
Language:English
Published: PAGEPress Publications 2015-02-01
Series:Mediterranean Journal of Hematology and Infectious Diseases
Subjects:
acquired hemophilia
inhibitors
rituximab
Online Access:http://www.mjhid.org/index.php/mjhid/article/view/2185

Internet

http://www.mjhid.org/index.php/mjhid/article/view/2185

Similar Items